Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Early kynurenergic impairment in Huntington's disease and in a transgenic animal model.

Neuroscience letters - 14 Apr 2000

Guidetti P, Reddy P H, Tagle D A, Schwarcz R

Abstract excerpt

Several neuroactive metabolites of the kynurenine pathway of tryptophan degradation have been speculatively linked to the pathophysiology of Huntington's Disease (HD). Here we demonstrate that the levels of two of these metabolites, the free radical generator 3-hydroxykynurenine (3HK) and the neuroprotectant kynurenate (KYNA), are increased in the neostriatum of stage 1 HD patients and in the brain of mice...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Huntingtin Protein
Share to Huntington Disease
Share to Kynurenine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Inbred Strains

Share to Neocortex

Share to Neostriatum

Share to Neuroprotective Agents

Share to Neurotoxins

Source

Identifiers

PMID: 10754231
DOI: 10.1016/s0304-3940(00)00956-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Early kynurenergic impairment in Huntington's disease and in a transgenic animal model.PMID 10754231Read ↗

Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease.Semantic proximity Read ↗

Age-dependent alterations of the kynurenine pathway in the YAC128 mouse model of Huntington disease.Semantic proximity Read ↗

The causative role and therapeutic potential of the kynurenine pathway in neurodegenerative diseaseSemantic proximity Read ↗

Integrative hypothesis for Huntington's disease: a brief review of experimental evidence.Semantic proximity Read ↗

Study of oxidative damage and antioxidant systems in two Huntington's disease rodent models.Semantic proximity Read ↗

Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington’s diseaseSemantic proximity Read ↗

The Kynurenine Pathway Modulates Neurodegeneration in a Drosophila Model of Huntington's DiseaseSemantic proximity Read ↗

Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington's disease.Semantic proximity Read ↗

Mice transgenic for the Huntington's disease mutation are resistant to chronic 3-nitropropionic acid-induced striatal toxicity.Semantic proximity Read ↗

Histone deacetylase inhibition modulates kynurenine pathway activation in yeast, microglia, and mice expressing a mutant huntingtin fragment.Semantic proximity Read ↗

Analog of Kynurenic Acid Decreases Tau Pathology by Modulating Astrogliosis in Rat Model for TauopathySemantic proximity Read ↗

Expanded CAG repeats in exon 1 of the Huntington's disease gene stimulate dopamine-mediated striatal neuron autophagy and degenerationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.